Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.43 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.43 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.42 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | CASP6 | P55212 | 1/20 | 0.42 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.42 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.42 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28642675 | 0.81 | HPGD (0.42) | HPGDNOTUMOPRM1OPRK1KMT2A | |
| SCHEMBL11404877 | 0.81 | POLB (0.56) | NOTUMOPRM1OPRK1OPRL1KMT2A | |
| SCHEMBL29765632 | 0.77 | HPGD (0.59) | HPGDNOTUMOPRM1OPRK1OPRL1 | |
| SCHEMBL1464486 | 0.76 | HPGD (0.57) | HPGDNOTUMOPRM1OPRK1OPRL1 | |
| SCHEMBL30642159 | 0.76 | HPGD (0.57) | HPGDNOTUMOPRM1OPRK1OPRL1 | |
| SCHEMBL3641405 | 0.76 | HPGD (0.57) | HPGDNOTUMOPRM1OPRK1OPRL1 | |
| SCHEMBL16767079 | 0.74 | NOTUM (0.56) | HPGDNOTUMDDB1CRBNKMT2A | |
| SCHEMBL1462133 | 0.74 | HPGD (0.55) | HPGDNOTUMOPRM1OPRK1OPRL1 | |
| SCHEMBL6701389 | 0.74 | HPGD (0.55) | HPGDNOTUMOPRM1OPRK1OPRL1 | |
| SCHEMBL578262 | 0.74 | NOTUM (0.56) | HPGDNOTUMDDB1CRBNKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2723336-B1 | COMPOSITIONS FOR THE TREATMENT OF FRAGILE X SYNDROME | CENTRE NAT RECH SCIENT (FR) | 2020-04-08 | — | — | EP | claimed |
| US-10265300-B2 | Methods of treating seizure disorders | OVID THERAPEUTICS INC. (US) | 2019-04-23 | — | — | US | claimed |
| US-20180243266-A1 | METHODS OF TREATING SEIZURE DISORDERS | OVID THERAPEUTICS INC. | 2018-08-30 | — | — | US | claimed |
| WO-2018157046-A1 | METHODS OF TREATING SEIZURE DISORDERS | OVID THERAPEUTICS INC. (US) | 2018-08-30 | — | — | WO | claimed |
| US-20140221450-A1 | Compositions for the treatment of Fragile X syndrome | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2014-08-07 | — | — | US | claimed |
| EP-2723336-A1 | COMPOSITIONS FOR THE TREATMENT OF FRAGILE X SYNDROME | Centre National De La Recherche Scientifique (FR) | 2014-04-30 | — | — | EP | claimed |
| WO-2013001412-A1 | COMPOSITIONS FOR THE TREATMENT OF FRAGILE X SYNDROME | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2013-01-03 | — | — | WO | claimed |
| EP-2540295-A1 | Compositions for the treatment of Fragile X syndrome | Centre national de la recherche scientifique (FR) | 2013-01-02 | — | — | EP | claimed |
| EP-1330426-A4 | SELECTIVE MAXI-K- POTASSIUM CHANNEL OPENERS FUNCTIONAL UNDER CONDITIONS OF HIGH INTRACELLULAR CALCIUM CONCENTRATION, METHODS AND USES THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2005-09-14 | — | — | EP | claimed |
| US-20050043293-A1 | Selective maxi-K potassium channel openers functional under conditions of high intracellular calcium concentration, methods and uses thereof | GRIBKOFF VALENTIN K (US) | 2005-02-24 | — | — | US | claimed |
| EP-1330426-A1 | SELECTIVE MAXI-K- POTASSIUM CHANNEL OPENERS FUNCTIONAL UNDER CONDITIONS OF HIGH INTRACELLULAR CALCIUM CONCENTRATION, METHODS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-07-30 | — | — | EP | claimed |
| WO-2002030868-A1 | SELECTIVE MAXI-K- POTASSIUM CHANNEL OPENERS FUNCTIONAL UNDER CONDITIONS OF HIGH INTRACELLULAR CALCIUM CONCENTRATION, METHODS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-04-18 | — | — | WO | claimed |
| US-20020045566-A1 | Selective maxi-K potassium channel openers functional under conditions of high intracellular calcium concentration, methods and uses thereof | BRISTOL-MYERS SQUIBB COMPANY | 2002-04-18 | — | — | US | claimed |
| WO-2025235367-A1 | AZAINDOLINONE COMPOUNDS AS KCA3.1 POTASSIUM CHANNEL BLOCKERS | D. E. SHAW RESEARCH, LLC (US) | 2025-11-13 | — | — | WO | disclosed |
| CN-111587239-B | Method for producing lactam compound and lactam compound produced by the method | 基础科学研究院 | 2024-04-02 | — | — | CN | disclosed |
| WO-2023160708-A1 | INDOLONE-SUBSTITUTED-1,3-THIAZOLIDINONE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 复旦大学 | 2023-08-31 | — | — | WO | disclosed |
| CN-1009197-B | Process for preparing N, 3-disubstituted 2-oxindole-1-carboxamides | PFIZER (US) | 1990-08-15 | — | — | CN | disclosed |
| US-4123543-A | ANTIDEPRESSANTS | AB KABI (SE) | 1978-10-31 | — | — | US | disclosed |
| US-4117144-A | ANTIDEPRESSANTS | AB KABI (SE) | 1978-09-26 | — | — | US | disclosed |
| US-3947451-A | TREATMENT OF PSYCHIATRIC AND PSYCHOSOMATIC DISEASES | AB KABI (SW) | 1976-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10265300-B2 | Methods of treating seizure disorders | KCNJ2, HCN2, CACNA1I | HPGD 1505/4885NOTUM 1731/4885OPRM1 611/4885 |
| US-20180243266-A1 | METHODS OF TREATING SEIZURE DISORDERS | KCNJ2, HCN2, CACNA1I | HPGD 1505/4885NOTUM 1731/4885OPRM1 611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.